An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech And/or F. Hoffmann-La Roche Ltd-Sponsored Trastuzumab Emtansine Study

Trial Profile

An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech And/or F. Hoffmann-La Roche Ltd-Sponsored Trastuzumab Emtansine Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs Trastuzumab emtansine (Primary) ; Docetaxel; Paclitaxel; Pertuzumab; Trastuzumab
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Acronyms T-DM1 study
  • Sponsors Chugai Pharmaceutical; Genentech; Roche
  • Most Recent Events

    • 14 Mar 2017 Planned number of patients changed from 500 to 720.
    • 14 Mar 2017 Planned End Date changed from 1 Sep 2022 to 28 Feb 2022.
    • 14 Mar 2017 Planned primary completion date changed from 1 Sep 2022 to 30 Dec 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top